Donald P. Lawrence, MD

Lecturer, Department of Medicine, Harvard Medical School

Clinical Director, Center for Melanoma, Massachusetts General Hospital

Contact Info

Donald Lawrence
Massachusetts General Hospital
55 Fruit St

Boston, MA, 02114
Mailstop: YAW 9E
Phone: 617-643-3614
Fax: 617-724-6898
dplawrence@partners.org

Assistant

Pamela Dicicco
Assistant
Center for Melanoma
Massachusetts General Hospital
55 Fruit Street
Boston, MA, 02114
Mailstop: Yawkey 9E
Phone: 617-643-3614
Fax: 617-724-6898
pdicicco@partners.org

DF/HCC Program Affiliation

Cutaneous Oncology and Melanoma

Research Abstract

Dr. Lawrence’s research focuses on the development of novel therapies for melanoma. He leads numerous melanoma clinical trials within the Dana-Farber/Harvard Cancer Center. He is the principal investigator of two NCI-funded, multicenter clinical trials evaluating targeted therapies in cancers selected by prospective genotypic analysis: an intergroup trial of a c-kit inhibitor for the subset of melanomas that harbor mutations in that gene, and a trial of a MEK inhibitor in cancers other than melanoma with BRAF mutations. Dr. Lawrence also has a research interest in immunotherapy for melanoma.

Publications

View All Publications

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Donald P. Lawrence, MD Lecturer, Department of Medicine, Harvard Medical School Clinical Director, Center for Melanoma, Massachusetts General Hospital Contact Info Donald Lawrence Massachusetts General Hospital 55 Fruit St Boston, MA, 02114 Mailstop: YAW 9E Phone: 617-643-3614 Fax: 617-724-6898 dplawrence@partners.org Assistant Pamela Dicicco Assistant Center for Melanoma Massachusetts General Hospital 55 Fruit Street Boston, MA, 02114 Mailstop: Yawkey 9E Phone: 617-643-3614 Fax: 617-724-6898 pdicicco@partners.org DF/HCC Program Affiliation Cutaneous Oncology and Melanoma Research Abstract Dr. Lawrence’s research focuses on the development of novel therapies for melanoma. He leads numerous melanoma clinical trials within the Dana-Farber/Harvard Cancer Center. He is the principal investigator of two NCI-funded, multicenter clinical trials evaluating targeted therapies in cancers selected by prospective genotypic analysis: an intergroup trial of a c-kit inhibitor for the subset of melanomas that harbor mutations in that gene, and a trial of a MEK inhibitor in cancers other than melanoma with BRAF mutations. Dr. Lawrence also has a research interest in immunotherapy for melanoma. Publications View All Publications
Site Map Site Feedback Web Privacy Policy